Helle Heibroch Laustsen, PhD, serves as Senior Director, Program Leadership at Hemab, where she leads programs from candidate selection through early clinical development. With over 17 years of experience in drug discovery and development, Helle began her career in research at Novo Nordisk in the Hemophilia space, where she led early innovation teams in the pre-clinical area and played a key role in advancing novel therapies within the hemophilia space e.g., Alhemo®. More recently, she held Program Lead positions at Leo Pharma and Genmab, where she successfully led antibody projects within dermatology and oncology from discovery and preclinical development through to first human dose. Helle earned her Ph.D. from the Faculty of Natural Sciences at Aarhus University, Denmark.